Add like
Add dislike
Add to saved papers

miR-29a inhibits human retinoblastoma progression by targeting STAT3.

Oncology Reports 2018 Februrary
Retinoblastoma (RB) is the most common malignancy that occurs during childhood. Growing evidence supports a crucial role for microRNAs (miRNAs) in regulating the initiation and progression of RB. Aberrant expression of microRNA‑29a (miR‑29a) has been found in many types of cancers, but not including RB. Therefore, the aims of the present study were to evaluate the regulatory role and underlying mechanism of miR‑29a in human RB. In the present study, we found that miR‑29a expression was significantly downregulated in RB tissues and cell lines. Overexpression of miR‑29a in RB cells significantly inhibited cell proliferation, migration, and invasion and promoted cell apoptosis in vitro. Additionally, signal transducer and activator of transcription 3 (STAT3) was identified as a direct target of miR‑29a in RB cells. miR‑29a overexpression in RB cells not only inhibited STAT3 expression but also altered expression of its downstream genes, including, Bcl2, cyclin D1 and matrix metalloproteinase 2 (MMP‑2). STAT3 mRNA expression was upregulated in RB tissues and negatively correlated with miR‑29a expression. Reintroduction of STAT3 without 3'‑untranslated region (3'UTR) reversed the inhibitory effects of miR‑29a on cell proliferation, migration and invasion. In vivo study confirmed that overexpression of miR‑29a also inhibited tumor formation of RB in a nude mouse model by repressing STAT3. Collectively, these data suggest that miR‑29a exerts a tumor suppressor effect on RB by repressing STAT3, supporting the targeting of miR‑29a as a potentially effective therapeutic method for RB.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app